HPV-independent cervical cancer reports
Author | Sample histology | Negative cases N (%) | Negative results according to sample histology | Technique |
Riou et al48 | 89 SQ, 17 ADC | 17/106 (16.03) | 15 SQ, 2 ADC | Southern blot, PCR |
Shikano et al32 | 39 ADC | 14/39 (14.35) | 14 ADC | CISH |
Brewer et al34 | 30 LCNK, 23 LCK, 7 ADC, 5 ADS, 1 CC | 5/66 (7.57) | Not reported | MY09/11 – E6 |
Lo et al51 | 107 SQ, 14 ADC | 26/121 (21.48) | 23 SQ, 3 ADC | MY09/11 - sequencing |
Kedzia et al33 | 47 SQ | 15/47 (31.91) | 15 SQ | MY09/11 – E6 |
Park et al35 | 26 ADC unusuals | 26/26 (100) | 26 ADC unusuals | SPF10-LiPA system |
Xu et al39 | 13 SQ, 25 ADC | 17/38 (44.73) | 4 SQ, 13 ADC | Multiplex PCR |
Liu et al40 | 89 SQ, 10 ADC, 2 CC, 1 undifferentiated | 14/101 (13.86) | Not reported | E6/E7 mRNA |
Rodríguez-Carunchio et al50 | 104 SQ, 32 ADC | 8/136 (5.88) | 3 SQ, 5 ADC | HC2, SPF10-LiPA system, GP5+/6+, E7-specific assay |
Omori et al36 | 36 ADC usual, 8 ADC gastric | 14/44 (31.81) | 6 ADC usuals, 8 ADC gastrics | ISH, PCR |
Park et al31 | 50 SQ, 2 ADC | 15/52 (28.84) | Not reported | E6/E7 mRNA |
Burk et al4 | 144 SQ, 31 ADC, 3 ADS | 9/178 (5.05) | 4 SQ, 5 ADC | RNA seq |
Banister et al42 | 212 SQ, 44 ADC, 5 ADS | 20/261 (7.70) | 10 SQ, 8 ADC, 2 ADS | RNA seq (E6E7/total genes) |
Chong et al52 | 210 SQ, 38 ADC/ADS | 46/248 (18.50) | 33 SQ, 13 ADC/ADS | PAN Array HPV Genotyping Chip/Anyplex II HPV28 |
Nicolás et al37 | 168 SQ, 39 ADC, 4 ADS, 3 neuroendocrines | 21/214 (9.81) | 12 SQ, 6 ADC, 1 ADS, 2 neuroendocrines | SPF10-LiPA system |
Kaliff et al55 | 169 SQ, 27 ADC, 4 ADS, 2 neuroendocrines | 14/202 (6.9) | 3 SQ, 9 ADC, 2 ADS | Anyplex II HPV28, RT-PCR E6/E7 |
ADC, adenocarcinoma; ADS, adenosquamous; CC, clear cells; CISH, chromogenic in situ hybridization; HPV, human papillomavirus; ISH, in situ hybridization; LCK, large cell keratinizing; LCNK, large cell non-keratinizing; PCR, polymerase chain reaction; SQ, squamous.